Navidea Biopharmaceuticals Announces Scientific Presentations Of Results From Lymphoseek® Studies At The European Association Of Nuclear Medicine And European Society Of Surgical Oncology Meetings

Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB) today announced that data and results from its Lymphoseek® (technetium Tc 99m tilmanocept) injection studies in breast cancer, melanoma or head and neck cancer were recently presented at the European Association of Nuclear Medicine Congress in Gothenberg, Sweden and will be presented this week at the European Society of Surgical Oncology-British Association of Surgical Oncology Congress from October 29-31, 2014 in Liverpool, UK.

Help employers find you! Check out all the jobs and post your resume.